| 1/46 | US=34 / Câncer Rio MCP. Síndrome hereditária de cânceres de mama e colorretal. In: Guimarães JRQ. Manual de oncologia. 3ª ed. São Paulo: BBS Editora, 2008. p. 157-61. GENE CHEK2 (CELL CYCLE CHECKPOINT KINASE 2); CHECK2 COMO GENE DE SUSCETIBILIDADE AO CANCER; CHEK2 1100DELC; QUADRO CLINICO |
| 2/46 | US=47 / Câncer Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. 314 p. (Cancer Drug Discovery and Development). ISBN 978-1-58829-930-7. |
| 3/46 | US=58 / Câncer Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. 424 p. (Cancer Drug Discovery and Development Series). ISBN 978-1-60761-177-6. |
| 4/46 | US=6 / Quimioterapia Airley R. Checkpoint protein kinases as novel targets - mammalian target of rapamycin (mTOR). In: ___. Cancer chemotherapy: basic science to the clinic. New Jersey: John Wiley & Sons, 2009. p. 245-8. ISBN 978-0-470-09254-5. CHECKPOINT; PROTEINAS QUINASES; MTOR; ALVO DA RAPAMICINA EM MAMIFEROS; ATIVACAO DE MTOR; ANTICANCERIGENOS ALVO MTOR |
| 5/46 | US=47 / Câncer Knudsen ES, Braden WA. RB-pathway: cell control and cancer therapy. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 1-17. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. VIA RB; CONTROLE DO CANCER; TERAPIA CELULAR; SUPRESSOR DE TUMOR; RETINOBLASTOMA; CICLINAS; QUIMIOTERAPIA; TERAPIA DE ALVO MOLECULAR; CICLO CELULAR; E2F; ANTIMETABOLITOS; AGENTES ANTIMICROTUBULOS |
| 6/46 | US=47 / Câncer Klein C, Vassilev LT. Targeting the p53/MDM2 pathway for cancer therapy. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 19-56. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. SEGMENTACAO DA VIA P53/MDM2; TERAPIA DE CANCER; PROTEINA P53; MDM2; SUPRESSOR DE TUMOR; INTERACAO PROTEINA-PROTEINA; INTERACAO P53-MDM2 |
| 7/46 | US=47 / Câncer Bender RP, Osheroff N. DNA topoisomerases as targets for the chemotherapeutic treatment of cancer. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 57-91. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. TOPOISOMERASES DE DNA; CANCER. TERAPIA; QUIMIOTERAPIA; TOPOISOMERASE II; TOPOISOMERASE IIALFA; TOPOISOMERASE IIBETA; TOPOISOMERASE II POISONS; FARMACOS ANTICANCERIGENOS; GENOTOXICIDADE; LEUCEMIA; DNA SUPERCOILING; LESAO DNA |
| 8/46 | US=47 / Câncer Ackermann JM, El-Deiry WS. Targeting ATM/ATR in the DNA damage checkpoint. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 93-116. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. SEGMENTACAO ATM/ATR; DANOS AO DNA; ATAXIA TELANGIECTASIA; RADIACAO IONIZANTE; FOSFORILACAO |
| 9/46 | US=47 / Câncer Kawabe T. Compounds that abrogate the G2 checkpoint. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 117-33. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. CICLO CELULAR; G1; G2; ONCOGENESE; TERAPIA DO CANCER; DANOS AO DNA; REPARO DO DNA; MUTACAO |
| 10/46 | US=47 / Câncer Yap TA, Molife LR, Bono JS. CDK inhibitors as anticancer agents. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 135-62. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DE CDK; AGENTES ANTICANCERIGENOS; CICLO CELULAR; CICLINA DEPENDENTE DE QUINASE; CICLINA; INIBIDOR; FLAVOPIRIDOL; UCN-01; E7070; SELICICLIB; BMS 387032; ZD 304709 |
| 11/46 | US=47 / Câncer Toyota M, Kashima L, Tokino T. CHFR as a potential anticancer target. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 163-76. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. CHFR; AGENTE ANTICANCERIGENO; CHECKPOINT MITOTICO; CHECKPOINT PROFASE; TUBULINA; UBIQUITINA LIGASE E3; MITOSE |
| 12/46 | US=47 / Câncer Villalona-Calero MA, Schaaf L, Turowski R. Antimicrotubule agents. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 177-205. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. AGENTES ANTIMICROTUBULOS; TUBULINA; ALCALOIDES DA VINCA; TAXANOS; EPOTILONAS; RESISTENCIA TUMOR; ALBUMINA |
| 13/46 | US=47 / Câncer Sarli V, Giannis A. Kinesin motor inhibitors as effective anticancer drugs. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 207-26. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES KINESIN; DROGAS ANTICANCER; KINESINAS; ANTIMITOTICOS; EG5 HUMANA |
| 14/46 | US=47 / Câncer Kang J, Yu H. Targeting the spindle checkpoint in cancer chemotherapy. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 227-41. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. SEGMENTACAO DO CHECKPOINT MITOTICO; QUIMIOTERAPIA; MITOSE; SEGREGACAO DOS CROMOSSOMOS; CHECKPOINT MITOTICO; ANEUPLOIDIA; ANAFASE; UBIQUITINACAO; ANTIMITOTICOS; MAD2; CDC20; BUB1 |
| 15/46 | US=47 / Câncer Shakalya K, Mahadevan D. Antiproliferation inhibitors targeting aurora kinases. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 243-69. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES ANTI-PROLIFERACAO; AURORA QUINASE; MITOSE; CICLO CELULAR; PROTO-ONCOGENES; INIBIDORES DA PROTEINA-QUINASE; ANEUPLOIDIA; CITOCINESE |
| 16/46 | US=47 / Câncer Dai W, Yang Y, Jiang N. Plks as novel targets for cancer drug design. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 271-90. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. PLKS; MEDICAMENTO ANTICANCER; POLO-LIKE QUINASES; PLK1; MITOSE; INIBIDORES; DROGAS ANTI-CANCER; FOSFORILACAO |
| 17/46 | US=47 / Câncer Gabrielli B, Stevens F, Beamish H. Do histone deacetylase inhibitors target cell cycle checkpoints that monitor heterochromatin structure?. In: Dai W. Checkpoint responses in cancer therapy. New Jersey: Humana Press, 2008. p. 291-309. (Cancer Drug Discovery and Development) ISBN 978-1-58829-930-7. INIBIDORES DAS HISTONAS DESACETILASES; CONTROLE DO CICLO CELULAR; HETEROCROMATINA; LETALIDADE SINTETICA; PASSAGEIROS CROMOSSOMICOS |
| 18/46 | US=58 / Câncer Dijkstra KK, Blanchetot C, Boonstra. Evasion of G1 checkpoints in cancer. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 3-26. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CONTROLE G1 EM CANCER; CICLO CELULAR; CHECKPOINT G1 CEDO; PONTO DE RESTRICAO; ESTRESSE MITOGENICA HIPER; CHECKPOINT ENERGIA; ROS |
| 19/46 | US=58 / Câncer Hurley PJ, Bunz F. Distinct pathways involved in s-phase checkpoint control. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 27-36. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. CONTROLO S-CHECKPOINT; INTRA-S-FASE CHECKPOIN; CHECKPOIN REPLICACAO; S-M CHECKPOINT; ATR; CHK1; CHK2; REPLICACAO DO DNA |
| 20/46 | US=58 / Câncer Kuang J, Wang R. Mechanisms of G2 phase arrest in DNA damage-induced checkpoint response. In: Siddik ZH. Checkpoint controls and targets in cancer therapy. New Jersey: Humana Press, 2008. p. 37-51. (Cancer Drug Discovery and Development Series) ISBN 978-1-60761-177-6. G2 CHECKPOINT; CDC25; PP2A; 14-3-3; 14-3-3O; P53; P21; GADD45 |